Golf protein levels in rat striatum are increased by chronic antidepressant administration and decreased by olfactory bulbectomy

Life Sciences

Volumn 79, Issue 5, 2006, Pages 462-468

  Taoka, Hideki ^a   Hamamura, Takashi ^a,b   Endo, Shiro ^c   Miki, Masahito ^d   Lee, Youmei ^e   Miyata, Shinji ^a   Toma, Kishio ^f   Ishihara, Takeshi ^a   Sagara, Hidenori ^g   Gomita, Yutaka ^g   Kuroda, Shigetoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Hamamura Clinic   (Japan)

^c Fujisawa Municipal Hospital   (Japan)

^d Takaoka Hospital   (Japan)

^e Mannari Hospital   (Japan)

^f OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^g OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Anhedonia; Bulbectomy; Depression; Dopamine; G protein; Imipramine; Motivation; NRI; Nucleus accumbens; SSRI

Indexed keywords

ANTIDEPRESSANT AGENT; COCAINE; DOPAMINE 1 RECEPTOR; FLUVOXAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; IMIPRAMINE; MAPROTILINE;

ALPHA CHAIN; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG EFFICACY; HYPOTHESIS; MALE; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY BULB; OLFACTORY BULBECTOMY; PROTEIN EXPRESSION; PUTAMEN; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; COCAINE; GTP-BINDING PROTEIN ALPHA SUBUNITS; IMIPRAMINE; MALE; NEOSTRIATUM; OLFACTORY BULB; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; UP-REGULATION;

EID: 33745070336     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.01.033     Document Type: Article

References (54)

1. olf are anosmic. Neuron 20 1 (1998) 69-81
2. Bergstrom D.A., and Kellar K.J. Adrenergic and serotonergic receptor binding in rat brain after chronic desmethylimipramine treatment. The Journal of Pharmacology and Experimental Therapeutics 209 2 (1979) 256-261
3. Blackshear M.A., and Sanders-Bush E. Serotonin receptor sensitivity after acute and chronic treatment with mianserin. The Journal of Pharmacology and Experimental Therapeutics 221 2 (1982) 303-308
4. Blier P., and de Montigny C. Current advances and trends in the treatment of depression. Trends in Pharmacological Sciences 15 7 (1994) 220-226
5. Bouckoms A., and Mangini L. Pergolide: an antidepressant adjuvant for mood disorders?. Psychopharmacology Bulletin 29 2 (1993) 207-211
6. Bouras N., and Bridges P.K. Bromocriptine in depression. Current Medical Research and Opinion 8 3 (1982) 150-153
7. αolf is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. Journal of Neurochemistry 76 5 (2001) 1585-1588
8. olfα levels after amphetamine- and cocaine-induced behavioral sensitization. Synapse 51 4 (2004) 241-248
9. Cryan J.F., Markou A., and Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends in Pharmacological Sciences 23 5 (2002) 238-245
10. 1 receptor agonists in the behavioural despair animal model of depression. European Journal of Pharmacology 262 1-2 (1994) 107-111
11. Dailly E., Chenu F., Renard C.E., and Bourin M. Dopamine, depression and antidepressants. Fundamental and Clinical Pharmacology 18 6 (2004) 601-607
12. s α and cyclic AMP-dependent protein kinase. Pharmacologist 31 (1989) 182
13. Durlach-Misteli C., and Van Ree J.M. Dopamine and melatonin in the nucleus accumbens may be implicated in the mode of action of antidepressant drugs. European Journal of Pharmacology 217 1 (1992) 15-21
14. 2 dopamine receptors in the rat brain. Journal of Neural Transmission 104 4-5 (1997) 515-524
15. Dziedzicka-Wasylewska M., Willner P., and Papp M. Changes in dopamine receptor mRNA expression following chronic mild stress and chronic antidepressant treatment. Behavioural Pharmacology 8 6-7 (1997) 607-618
16. Eisch A.J., Bolanos C.A., de Wit J., Simonak R.D., Pudiak C.M., Barrot M., Verhaagen J., and Nestler E.J. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biological Psychiatry 54 10 (2003) 994-1005
17. Fibiger H.C., and Phillips A.G. Mesocorticolimbic dopamine systems and reward. Annals of the New York Academy of Sciences 537 (1988) 206-215
18. Gomita Y., Ogawa N., and Ueki S. Effect of bilateral olfactory bulbectomy on discrimination avoidance conditioning in rats. Physiology & Behavior 32 6 (1984) 1011-1016
19. 1 receptor with adenylyl cyclase. The Journal of Neuroscience 13 5 (1993) 2237-2248
20. Inoue T., Tsuchiya K., Miura J., Sakakibara S., Denda K., Kasahara T., and Koyama T. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biological Psychiatry 40 2 (1996) 151-153
21. Izumi T., Inoue T., Kitagawa N., Nishi N., Shimanaka S., Takahashi Y., Kusumi I., Odagaki Y., Denda K., Ohmori T., and Koyama T. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. Journal of Affective Disorders 61 1-2 (2000) 127-132
22. Jimerson D.C. Role of dopamine mechanisms in affective disorders. In: Meltzer H.Y. (Ed). Psychopharmacology: The Third Generation of Progress (1987), New York 505-511
23. Kelly J.P., Wrynn A.S., and Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacology & Therapeutics 74 3 (1997) 299-316
24. Kendall D.A., and Nahorski S.R. 5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: pharmacological characterization and effects of antidepressants. The Journal of Pharmacology and Experimental Therapeutics 233 2 (1985) 473-479
25. Lee Y., Hamamura T., Ohashi K., Fujiwara Y., and Kuroda S. The effect of lithium on methamphetamine-induced regional Fos protein expression in the rat brain. NeuroReport 10 5 (1999) 895-900
26. Lee Y., Hamamura T., Ohashi K., Miki M., Fujiwara Y., and Kuroda S. Carbamazepine suppresses methamphetamine-induced Fos expression in a regionally specific manner in the rat brain. Possible neural substrates responsible for antimanic effects of mood stabilizers. Neuropsychopharmacology 22 5 (2000) 530-537
27. Lesch K.P., and Manji H.K. Signal-transducing G proteins and antidepressant drugs: evidence for modulation of alpha subunit gene expression in rat brain. Biological Psychiatry 32 7 (1992) 549-579
28. oα subunits. European Journal of Pharmacology 207 4 (1991) 361-364
29. Maj J., Rogoz Z., Skuza G., and Sowinska H. Repeated treatment with antidepressant drugs potentiates the locomotor response to (+)-amphetamine. Journal of Pharmacy and Pharmacology 36 2 (1984) 127-130
30. Maj J., Rogoz Z., Skuza G., and Sowinska H. Repeated treatment with antidepressant drugs increases the behavioural response to apomorphine. Journal of Neural Transmission 60 3-4 (1984) 273-282
31. Maj J., Wedzony K., and Klimek V. Desipramine given repeatedly enhances behavioural effects of dopamine and d-amphetamine injected into the nucleus accumbens. European Journal of Pharmacology 140 2 (1987) 179-185
32. Manji H.K., Drevets W.C., and Charney D.S. The cellular neurobiology of depression. Nature Medicine 7 5 (2001) 541-547
33. γ7) and adenylyl cyclase expressed specifically in the rat striatum. European Journal of Pharmacology 428 3 (2001) 303-309
34. Miyata S., Hamamura T., Lee Y., Miki M., Habara T., Oka T., Endo S., Taoka H., and Kuroda S. Contrasting Fos expression induced by acute reboxetine and fluoxetine in the rat forebrain: neuroanatomical substrates for the antidepressant effect. Psychopharmacology (Berl) 177 3 (2005) 289-295
35. Naranjo C.A., Tremblay L.K., and Busto U.E. The role of the brain reward system in depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 25 4 (2001) 781-823
36. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., and Monteggia L.M. Neurobiology of depression. Neuron 34 1 (2002) 13-25
37. Nibuya M., Nestler E.J., and Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. The Journal of Neuroscience 16 7 (1996) 2365-2372
38. Nordin C., Siwers B., and Bertilsson L. Bromocriptine treatment of depressive disorders. Clinical and biochemical effects. Acta Psychiatrica Scandinavica 64 1 (1981) 25-33
39. 1) receptors by chronic imipramine is species-specific. Pharmacology, Biochemistry and Behavior 39 3 (1991) 769-771
40. Perrine S.A., Schroeder J.A., and Unterwald E.M. Behavioral sensitization to binge-pattern cocaine administration is not associated with changes in protein levels of four major G-proteins. Molecular Brain Research 133 2 (2005) 224-232
41. Plaznik A., and Kostowski W. The effects of antidepressants and electroconvulsive shocks on the functioning of the mesolimbic dopaminergic system: a behavioral study. European Journal of Pharmacology 135 3 (1987) 389-396
42. Randrup A., and Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology (Berl) 53 3 (1977) 309-314
43. Reith M.E., Li M.Y., and Yan Q.S. Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology (Berl) 134 3 (1997) 309-317
44. 3 receptors in the rat brain differentiated by agonist and antagonist binding-an autoradiographic analysis. Naunyn-Schmiedeberg's Archives of Pharmacology 359 3 (1999) 178-186
45. Rossetti Z.L., D'Aquila P.S., Hmaidan Y., Gessa G.L., and Serra G. Repeated treatment with imipramine potentiates cocaine-induced dopamine release and motor stimulation. European Journal of Pharmacology 201 2-3 (1991) 243-245
46. Salamone J.D., Cousins M.S., and Snyder B.J. Behavioral functions of nucleus accumbens dopamine: empirical and conceptual problems with the anhedonia hypothesis. Neuroscience and Biobehavioral Reviews 21 3 (1997) 341-359
47. Sitland-Marken P.A., Wells B.G., Froemming J.H., Chu C.C., and Brown C.S. Psychiatric applications of bromocriptine therapy. The Journal of Clinical Psychiatry 51 2 (1990) 68-82
48. Sulser F., Vetulani J., and Mobley P.L. Mode of action of antidepressant drugs. Biochemical Pharmacology 27 3 (1978) 257-261
49. Theohar C., Fischer-Cornelssen K., Brosch H., Fischer E.K., and Petrovic D. A comparative, multicenter trial between bromocriptine and amitriptyline in the treatment of endogenous depression. Arzneimittel-Forschung 32 7 (1982) 783-787
50. Vetulani J., and Sulser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 257 5526 (1975) 495-496
51. Waehrens J., and Gerlach J. Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients. Journal of Affective Disorders 3 2 (1981) 193-202
52. Willner P. Dopamine and depression: a review of recent evidence. II. Theoretical approaches. Brain Research 287 3 (1983) 225-236
53. Yadid G., Overstreet D.H., and Zangen A. Limbic dopaminergic adaptation to a stressful stimulus in a rat model of depression. Brain Research 896 1-2 (2001) 43-47
54. 1 receptor signaling. The Journal of Neuroscience 20 16 (2000) RC91